# Open-label inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients

Study · id `cardio:ct-nct06104423` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06104423](<https://clinicaltrials.gov/study/NCT06104423>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06104423

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 266 participants.

## Technical summary

Registry record NCT06104423. Non-randomized; no masking; primary purpose treatment. Start 2023-10-02 (actual); primary completion 2024-02-19 (actual). Results posted on 2025-04-24.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 266 participants (enrolled count; ClinicalTrials.gov record NCT06104423, source copy `cardio:ctgov-nct06104423-2025-04-24`, retrieved 2026-10-26)
- Started: 2023-10-02 (actual) (ClinicalTrials.gov record NCT06104423, source copy `cardio:ctgov-nct06104423-2025-04-24`, retrieved 2026-10-26)
- Primary completion: 2024-02-19 (actual) (ClinicalTrials.gov record NCT06104423, source copy `cardio:ctgov-nct06104423-2025-04-24`, retrieved 2026-10-26)
- Completion: 2024-02-19 (actual) (ClinicalTrials.gov record NCT06104423, source copy `cardio:ctgov-nct06104423-2025-04-24`, retrieved 2026-10-26)
- Results first posted: 2025-04-24 (ClinicalTrials.gov record NCT06104423, source copy `cardio:ctgov-nct06104423-2025-04-24`, retrieved 2026-10-26)
- Countries: Hungary (ClinicalTrials.gov record NCT06104423, source copy `cardio:ctgov-nct06104423-2025-04-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06104423-2025-04-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: Open-label inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients
- Acronym: ARTEMISIA
- Condition: Hypertension
- Intervention (Drug): Nebivolol 5 mg
- Intervention (Drug): Ramipril 2.5/5/10 mg
- Lead sponsor: Menarini International Operations Luxembourg SA
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Menarini International Operations Luxembourg SA (`cardio:org-menarini-international-operations-luxembourg-sa`)

## Provenance

Content hash: 772f848278fefc0c438543149f1970d567acc20eb37fb828736910ace682b601
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
